CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
Category: #health  | By Mateen Dalal  | Date: 2020-02-08 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various solid tumor cancers, such as brain-glioblastoma, melanoma, throat, stomach, lung, colon carcinoma, testicular, breast, ovarian, pancreas, uterine, bladder, among other indications. It is expecting to obtain preliminary outcomes on each subject within 3 to 4 weeks after the initial medication with leronlimab.  CytoDyn will continue to register patients in its metastatic breast cancer studies. 

The basket trial is a Phase 2 study with CCR5+ locally advanced or metastatic solid tumors including 30 subjects. Leronlimab will be administered subcutaneously as a weekly dose of 350 mg. Patients partaking in the trial will be allowed to receive and continue the standard-of-care chemotherapy as defined by the treating physician.

Bruce Patterson, M.D., Founder and Chief Executive Officer, IncellDx, an advisor and a diagnostic partner to CytoDyn, reportedly stated that the outcomes in patients with breast cancer have shown reduction in primary tumors, decrease in CTCs to zero, elimination or shrinking of metastatic lesions and remained stable for several weeks. Other trials demonstrated CTC levels in this cancer >5 and some as high as 20 per 4 mL of blood, he added.

Nader Pourhassan, Ph.D., Chief Executive Officer and President, CytoDyn, reportedly stated that if leronlimab  is able to demonstrate efficacy in this basket trial as the company has observed in the first 4 subjects in its MBC trials, the company will be able to file for another innovative therapy designation (BTD) for the multiple cancer indications evaluated in this study. Since the company started its cancer trials for mTNBC and compassionate usage and extended access for MBC, it has been receiving requests from subjects in the U.S. and overseas, he further added.

Source links:

https://www.cytodyn.com/newsroom/press-releases/detail/382/cytodyn-files-a-phase-2-basket-trial-with-leronlimab-pro

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...